JNJ‑4528-Investigation Treatment for R/R Multiple Myeloma, has it all (Breakthrough Designation, Effective Results & Excited KOLs)
Legend Biotech Corporation, announced the updated results from the Janssen sponsored Phase 1b/2 CARTITUDE-1 study (NCT03548207) evaluating the efficacy and safety of JNJ-68284528 (JNJ-4528) in multiple myeloma. There is something interesting about the drug, JNJ-4528 […]